A humanized CD16-CD33 BiKE (bispecific killer engager) antibody was demonstrated to strongly activate NK cells against CD33+ AML blasts when combined with pre-treatment with an ADAM17 small molecule inhibitor that prevented shedding of CD16 in vitro (142). The gene discussed is CD33; the disease is acute myeloid leukemia.